Urothelial Cancer
Responses to first- and second-line chemotherapy regimens for metastatic urothelial carcinoma (mUC) have been less than satisfactory, creating an unmet need for new treatment options for this disease.
Patients with metastatic urothelial cancer receive first-line treatment with platinum-based chemotherapy and second-line treatment with a checkpoint inhibitor.
Sacituzumab govitecan, a novel antibody-drug conjugate directed against Trop-2, induced response in nearly 33% of patients with heavily pretreated, relapsed, or refractory metastatic urothelial cancer.
The incidence of diabetes and urologic diseases is
widespread, and increases with age.
Results 1 - 5 of 5
